Co-Diagnostics Inc

Co-Diagnostics Inc (NASDAQ-CM : CODX) is a Utah based molecular diagnostics company having a unique PCR (Polymerase Chain Reaction) testing technology.

Investment Highlights - Co-Diagnostics Inc – Speculative Buy at USD 9.41

• The Company has shown a significant increase in financial performance in the financial year 2020, with higher cash flow from operating activities.
• In the last one year, the Company delivered a decent return of ~14.76% and delivered higher returns compared to the benchmark Index.
• As per valuation metrics, the EV/Sales and EV/EBITDA multiples of the Co-Diagnostics Inc are currently lower as compared to the corresponding multiples of the Healthcare Equipment & Supplies industry. It reflects, shares are undervalued as compared to the industry.
• From the technical standpoint, 14-day RSI is supporting an upside move (around 34 level), which means the stock price could increase in the short term.

Key Risks

• The covid-19 outbreak has resulted in supply chain and clinical trials disruptions which will have a negative impact on the Company’s performance.
• Any change in regulations and government policies could affect the overall business of the Company.

Financial Highlights – FY2020 (31 December 2020) (released on 25 March 2021)

(Source: Annual Report, Company Website) 

• For the financial year 2020, driven by higher sales of LogixSmart COVID-19 test throughout the world, the revenue increased significantly by 34580%.
• Driven by higher revenue, the profitability for the period increased significantly. The Company’s reported gross profit and net income increased significantly by 56424% and 786%, respectively.
• The cash balance as on 31 December 2020 increased to $42,976,713 (31 December 2019: $893,138).

One Year Share Price Chart

(Source: Refinitiv, Thomson Reuters)

Conclusion

The Company has shown a significant increase in financial performance in the financial year 2020. Both the revenue and profitability margins for the period increased. The Company witnessed an improvement in liquidity position along with well-positioned balance sheet. Co-Diagnostics believe that existing capital resources and cash generated from sales will be sufficient to meet next 12 months operating requirements. The Company expects available capital resources may be consumed more rapidly and it is looking to raise additional capital for strategic opportunities. Despite the impact of covid-19 on world economy, the Company is focused on driving growth across platform and executing business objectives. The stock made a 52-week low and high of USD 7.86 and USD 30.99, respectively.

Based on the decent growth prospects, we have given a “Speculative Buy” recommendation on Co-Diagnostics Inc at the closing price of USD 9.41 (as on 5 April 2021).

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.